OncoArendi Therapeutics SA (DE:1B1)
FRANKFURT:1B1
Total Valuation
OncoArendi Therapeutics SA has a market cap or net worth of €25.49M. The enterprise value is €97.52M.
Market Cap€25.49M
Enterprise Value€97.52M
Share Statistics
OncoArendi Therapeutics SA has 20,603,155 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding20,603,155
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
OncoArendi Therapeutics SA’s return on equity (ROE) is -0.18 and return on invested capital (ROIC) is -23.73%.
Return on Equity (ROE)-0.18
Return on Assets (ROA)-0.17
Return on Invested Capital (ROIC)-23.73%
Return on Capital Employed (ROCE)-0.24
Revenue Per Employee0.00
Profits Per Employee-153.81K
Employee Count102
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of OncoArendi Therapeutics SA is ―. OncoArendi Therapeutics SA’s PEG ratio is 0.17.
PE Ratio―
PS Ratio0.00
PB Ratio1.54
Price to Fair Value1.54
Price to FCF-6.95
Price to Operating Cash Flow-5.44
PEG Ratio0.17
Income Statement
In the last 12 months, OncoArendi Therapeutics SA had revenue of 0.00 and earned -15.69M in profits. Earnings per share was -0.77.
Revenue0.00
Gross Profit0.00
Operating Income-22.04M
Pretax Income-15.69M
Net Income-15.69M
EBITDA-19.03M
Earnings Per Share (EPS)-0.77
Cash Flow
In the last 12 months, operating cash flow was -19.97M and capital expenditures -3.74M, giving a free cash flow of -23.71M billion.
Operating Cash Flow-19.97M
Free Cash Flow-23.71M
Free Cash Flow per Share-1.15
Dividends & Yields
OncoArendi Therapeutics SA pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.36
52-Week Price Change-38.03%
50-Day Moving Average1.59
200-Day Moving Average1.60
Relative Strength Index (RSI)28.09
Average Volume (3m)0.00
Important Dates
OncoArendi Therapeutics SA upcoming earnings date is Apr 30, 2026, Before Open (Confirmed).
Last Earnings DateMar 31, 2026
Next Earnings DateApr 30, 2026
Ex-Dividend Date―
Financial Position
OncoArendi Therapeutics SA as a current ratio of 4.79, with Debt / Equity ratio of 6.05%
Current Ratio4.79
Quick Ratio4.79
Debt to Market Cap0.02
Net Debt to EBITDA0.58
Interest Coverage Ratio-286.48
Taxes
In the past 12 months, OncoArendi Therapeutics SA has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
OncoArendi Therapeutics SA EV to EBITDA ratio is -6.52, with an EV/FCF ratio of -6.39.
EV to Sales0.00
EV to EBITDA-6.52
EV to Free Cash Flow-6.39
EV to Operating Cash Flow-6.39
Balance Sheet
OncoArendi Therapeutics SA has €16.35M in cash and marketable securities with €5.29M in debt, giving a net cash position of €11.06M billion.
Cash & Marketable Securities€16.35M
Total Debt€5.29M
Net Cash€11.06M
Net Cash Per Share€0.54
Tangible Book Value Per Share€0.83
Margins
Gross margin is 66.49%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin66.49%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for OncoArendi Therapeutics SA is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―